Data are presented on a randomized study (stage II) which was undertaken to assess the efficacy of neoadjuvant chemotherapy (doxorubicin+paclitaxel) vis-a-vis endocrine therapy with aromatase inhibitors (anastrazole or exemestane) in postmenopausal women with ER-positive and/or PgR-positive tumors. Preoperative neoadjuvant chemotherapy was well tolerated and showed similar rates of overall response as compared with the latter regimen.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
neoadjuvant chemotherapy
8
[phase clinical
4
clinical trial
4
trial neoadjuvant
4
neoadjuvant hormone
4
hormone therapy
4
therapy comparison
4
comparison chemotherapy
4
chemotherapy patients
4
patients breast
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!